ASSEMBLY BIOSCIENCES, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0 | $6.3M |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Operating expenses | $84.4M | $73.9M | $71.8M | $94.1M | $138.9M |
| Cash from operations | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Capital expenditure | $66,000 | $28,000 | $255,000 | $102,000 | $3.1M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M |
| Impairments | — | — | — | — | $12.6M |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
Shares outstanding 15.9M · Free float 16.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.